Boehringer Ingelheim announces appointment of Vani Manja as India Country MD

India, 11 January 2021 – Boehringer Ingelheim has announced that Vani Manja is appointed Country Managing Director for India, effective January 1, 2021. In this role, she will assume responsibility for the Company’s businesses in India, Bangladesh, Nepal and Sri Lanka. Vani will also join the Board of the Company.

Vani succeeds Sharad Tyagi, who retired from Boehringer Ingelheim India on December 31, 2020 after over a decade of successful and dedicated service to the Company. During his tenure, Sharad built Boehringer Ingelheim India to be one of India’s fastest growing multinational pharmaceutical companies.

Announcing Vani’s appointment, Thorsten Poehl, Head of Emerging Markets, Boehringer Ingelheim said, “India presents a unique opportunity for Boehringer Ingelheim, wherein we affirm our commitment to patients and people in the country with our products and services. Vani is a proven and respected leader who lives our Company values and has a strong track record of leading complex transformations and delivering results. With her unwavering commitment to patients, customers and employees, I am confident that Vani will lead the India business to build patient-friendly access and benefit models in the years to come.

At this juncture, I would like to thank Sharad for his leadership in building a strong foundation to Boehringer Ingelheim India’s business. He has been instrumental in executing a successful high-growth strategy. I wish Sharad a great life after retirement, and Vani a successful and fulfilling career in Boehringer Ingelheim India.”

Vani was formerly the Global Head of Boehringer Ingelheim’s Go-To-Market and Business Steering organization, based in the Company’s headquarters in Germany. She joined Boehringer Ingelheim in the US in 2011, working across Strategy & Operations, Marketing and Sales leadership roles before moving to Ingelheim in 2016 as Regional Business Manager for Japan. Her global experience in Healthcare spans nearly two decades across McKinsey & Company, Becton Dickinson and Boehringer Ingelheim, and is characterized by strong global mobility and cross-functional leadership assignments across Healthcare and Management Consulting. Prior to embarking on her international career, she served as a commissioned officer in the Indian Army Ordnance Corps.

Vani holds an MBA and MA in International Studies from the Wharton School at the University of Pennsylvania in Philadelphia, and a Bachelor’s degree with Honors in Chemistry from Delhi University.

 Vani Manja, Country Managing Director, Boehringer Ingelheim India said, “I am excited and honored to return to India to lead a successful organization with a highly talented team. I look forward to working with our customers, partners and leaders in healthcare to improve the lives of patients through innovative therapies, after all the years of remotely following the huge strides India has taken towards developing healthcare.”

About Boehringer Ingelheim 
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

Since its inception in 2006, Boehringer Ingelheim in India has seen a high-growth trajectory aided by the launches of innovator products like Pradaxa, Trajenta, Actilyse, Giotrif (local brand name Xovoltib), Ofev (local brand name Cyendiv), Glyxambi and Jardiance.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

For further information, please contact –
Hitesh Garg
Archetype
E-mail: Hitesh.Garg@Archetype.co
Mob: +91 9833482728